Fewer Iowans are getting tested for COVID-19, and that’s making public health officials nervous. “Anytime you don’t know your status, you could certainly be spreading the virus unknowingly,” said Liz Highland, an advanced registered nurse practitioner at the clinic that manages the bulk of the University of Iowa’s COVID-19 testing. “That’s the biggest risk that people who have COVID are still out in the public and spreading it.” Over the last month, Dec. 21 through Wednesday, the median number of people tested each day in Iowa was 4,148, down 26 percent from the previous month’s daily median of 5,638 people tested, according to Gazette calculations based on the state’s COVID-19 dashboard.
Back in class, late-night shots, library hero: News from around our 50 states From USA TODAY Network and wire reports, USA TODAY Alabama Auburn: The top academic officer at Auburn University is facing a no-confidence vote this week by faculty members over lingering dissatisfaction with his handling of class scheduling around the coronavirus pandemic. The Opelika-Auburn News reports the University Senate is scheduled to meet Tuesday to address complaints against Provost Bill Hardgrave, who is being defended by President Jay Gouge. More than 500 faculty members met in a virtual gathering in November to discuss their concerns about Hardgrave and his insistence on returning to primarily in-person classes in the spring. Economics professor Mike Stern said Wednesday that his concerns still haven’t been adequately addressed. Hardgrave and other officials need to better assess teaching spaces and how to follow health guidelines about social distancing, he said. “I volunteered to teach face-to-face in the fall and spring (of the 2020-21 school year) and they promised it would be safe,” Stern said. “Then, they did the opposite.”
Iowa City, Iowa -University of Iowa Health Care is taking part in the Phase 3 clinical trial for the new Novavax COVID-19 vaccine. The medical center is enrolling 250 people to test the vaccine for its rate of success and safety. Participants will get two doses, and one-third of them will receive a placebo in the trial. University of Iowa Health Care previously took part in the clinical trial for the Pfizer vaccine, which is now being administered across the nation. Novavax uses a more traditional vaccine technology than the Pfizer and Moderna vaccines, which use mRNA to generate an immune response.
Iowa City, Iowa -University of Iowa Health Care is taking part in the Phase 3 clinical trial for the new Novavax COVID-19 vaccine. The medical center is enrolling 250 people to test the vaccine for its rate of success and safety. Participants will get two doses, and one-third of them will receive a placebo in the trial. University of Iowa Health Care previously took part in the clinical trial for the Pfizer vaccine, which is now being administered across the nation. Novavax uses a more traditional vaccine technology than the Pfizer and Moderna vaccines, which use mRNA to generate an immune response.
By Sue Danielson Jan 8, 2021 (Iowa City, IA) University of Iowa Health Care is taking part in COVID-19 vaccine trial. Researchers are testing a vaccine by Novavax. The multi-site clinical trial aims to enroll 30-thousand people, 250-in Iowa. Participants will get two doses of the vaccine, 21-days apart. “Different types of vaccines are helpful because certain people might respond better to one type of vaccine than another,” says Patricia Winokur, MD, executive dean of the University of Iowa Carver College of Medicine, and principal investigator for the UI trial site for the Novavax vaccine. Winokur also led the UI site for the clinical trial of the Pfizer-BioNTech vaccine.
By Sue Danielson Jan 8, 2021 (Iowa City, IA) University of Iowa Health Care is taking part in COVID-19 vaccine trial. Researchers are testing a vaccine by Novavax. The multi-site clinical trial aims to enroll 30-thousand people, 250-in Iowa. Participants will get two doses of the vaccine, 21-days apart. “Different types of vaccines are helpful because certain people might respond better to one type of vaccine than another,” says Patricia Winokur, MD, executive dean of the University of Iowa Carver College of Medicine, and principal investigator for the UI trial site for the Novavax vaccine. Winokur also led the UI site for the clinical trial of the Pfizer-BioNTech vaccine.
12/28/20 Officials at University of Iowa Health care are participating in a trial for a new COVID-19 vaccine. The Hospitals and Clinics were a trial site for the Pfizer-BioNTech vaccine earlier this year; the new vaccine comes from Novavax. The Cedar Rapids Gazette reports that the Novavax vaccine is much more like a traditional vaccine, using technology that developed the current flu vaccines. It will also require two doses, three weeks apart like the Pfizer vaccine. The UIHC will be recruiting about 250 participants for the trial, aged 18 and older. UIHC Executive Dean Patricia Winokur told the Gazette that researchers are specifically interested in recruiting people at high risk for severe COVID-19 infection, underrepresented populations, and front-line workers.
IOWA CITY - University of Iowa Health Care is expanding its role in the global effort to find vaccines against COVID-19 by beginning to enroll volunteers for another trial.
Please note that the posts on The Blogs are contributed by third parties. The opinions, facts and any media content in them are presented solely by the authors, and neither The Times of Israel nor its partners assume any responsibility for them. Please contact us in case of abuse. In case of abuse, Monday, December 14, 2020 was truly an historic day as the first doses of the anxiously-awaited COVID vaccination arrived at various hospitals and other venues throughout the country. These initial doses were given to high-risk workers. The recipients were grateful and upbeat. The general feelings were of pride to have played a major role in coping with the virus and relief that the vaccine is providing tangible evidence that we have turned the corner in our fight to defeat it.
Des Moines Register IOWA CITY, Ia. The COVID-19 vaccine didn’t feel any different from any of the other shots University of Iowa Hospitals and Clinics registered dietitian Sarah Davis has received over the years. A quick needle stick, and no pain, she said immediately after her shot Monday morning. The only difference between this shot and her others was that the faces of intensive care unit patients for whom she’s cared were flashing through her head. “It’s been a rough six months,” she said. “(The vaccine) just feels like a beginning to the end of all this. A light at the end of the tunnel.”